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Abstract - Angiotensin II receptor antagonists (ARBs) modulate the function of the renin-angiotensin-aldosterone system 
and are commonly prescribed antihypertensive drugs, especially in patients with renal failure. In this study, the rela-
tionship between several molecular properties of seven ARBs (candesartan, eprosartan, irbesartan, losartan, olmesartan, 
telmisartan, valsartan) and their fecal elimination data obtained from the literature were investigated. The ARB molecular 
descriptors were calculated using three software packages. Simple linear regression analysis showed the best correlation 
between fecal elimination data and lipophilicity descriptor, ClogP values (R2 = 0.725). Multiple linear regression was ap-
plied to examine the correlation of ARBs’ fecal elimination data with their lipophilicity and one additional, calculated 
descriptor. The best correlation (R2 = 0.909 with an acceptable probability value, P <0.05) was established between the ARB 
fecal elimination data and their lipophilicity and aqueous solubility data. Applying computed molecular descriptors for 
evaluating drug elimination is of great importance in drug research.
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INTRODUCTION
Angiotensin II receptor antagonists, also known as 
angiotensin receptor blockers (ARBs), AT1-recep-
tor antagonists or sartans, are a group of drugs that 
modulate the function of the renin-angiotensin-al-
dosterone system by antagonizing the vasoconstric-
tive and proinflammatory/pro-proliferative effects of 
angiotensin II (Csaba, 2011). They were introduced 
into clinical practice three decades ago and today are 
commonly prescribed for the treatment of hyperten-
sion, congestive heart failure and diabetic nephrop-
athy. They reduce cardiovascular risk and mortality, 
abate the level of albuminuria and exert beneficial 
renoprotective effect on the progression of diabetic 
kidney disease (Csaba, 2011; Lemke and Williams, 
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2008; Stella et al., 2007; Sweetman, 2009; Beale and 
Block, 2011).
There are eight currently available ARBs on the 
market: azilsartan, candesartan eprosartan, irbesar-
tan, losartan, olmesartan, telmisartan and valsartan. 
Although they all have the same indications for us-
age, they demonstrate differences in their pharma-
cology, pharmacokinetic and pharmacodynamic 
properties, which may affect their clinical efficacy. 
They are generally well tolerated and side effects, 
including cough, hyperkalemia, hypotension, dizzi-
ness, headache, drowsiness, diarrhea, abnormal taste 
sensation and rash are rare. They are contraindicated 
in pregnancy as they may cause birth defects (Lemke 
and Williams, 2008; Beale and Block, 2011; Moffat et 
al., 2011).
All ARBs are acidic drugs that will mostly be ion-
ized in physiological conditions. Most share a com-
mon tetrazole-biphenyl structure based on losartan. 
Telmisartan, in contrast, has a novel bisbenzimida-
zole structure, while eprosartan is a non-biphenyl 
non-tetrazole ARB (Csaba, 2011). They all have ade-
quate lipophilicity and their plasma protein binding 
values are relatively similar and high, ranging from 
95 to 100%. Candesartan cilexetil and olmesartan 
medoxomil differ from the other compounds since 
they are rapidly and completely hydrolyzed to their 
active metabolites, candesartan and olmesartan, 
respectively, in the intestinal wall (Lemke and Wil-
liams, 2008; Sweetman, 2009). Also, approximately 
14% of losartan oral dose is oxidized to more potent 
metabolites and none of the other ARBs are convert-
ed to active metabolites. The ARBs have a dual route 
of elimination, renal and fecal, which may be of im-
portance for patients with renal failure. According 
to data obtained from the relevant literature, their 
major route of elimination is fecal, ranging from 42-
97% (Lemke and Williams, 2008; Sweetman, 2009). 
A drug’s clinical success mostly depends on its 
absorption, distribution, metabolism or route of 
elimination (Di and Kernsy, 2003). Lipophilicity is 
one of the most important molecular properties that 
influence these values, but a number of other molec-
ular properties - molecular weight (Mw), molecular 
volume (Vol), polar surface area (PSA) and solubility 
data (logS), also play important roles in drug absorp-
tion, penetration into tissues, degree of distribution, 
degree of plasma protein binding and route of elim-
ination (Hartman and Schmitt, 2004; Remko et al., 
2006; Remko, 2007; Zhao, 2001). According to the 
available literature, a number of authors investigated 
drugs belonging to the ARBs group, their pharma-
cological properties as well as their similarities and 
differences (Cheung, 2004; Zwieten, 2006; Husain 
et al., 2011). Their acidity, lipophilicity, solubility or 
absorption was evaluated based on their molecular 
structure with the application of computer programs 
(Remko et al., 2006; Remko, 2007; Zhao, 2001). 
In our previous studies, we investigated the li-
pophilicity of several ACE inhibitors under different 
chromatographic conditions (Odovic et al., 2005; 
Odovic et al., 2006; Odovic et al., 2009) and the cor-
relation between ACE inhibitor lipophilicity data 
with their protein binding (PPB) data (Odovic and 
Trbojevic-Stankovic, 2012) or absorption (Odovic et 
al. 2012). In a recently published paper, the molec-
ular properties (molecular weight and volume val-
ues) of a selected group of ARBs were correlated in 
multiple linear regression (MLR) analysis with their 
PPB data (Odovic and Trbojevic-Stankovic, 2014). 
In continuation to these studies, the aim of this study 
was to compare the different molecular properties of 
seven ARBs (eprosartan, irbesartan, losartan, olm-
esartan, telmisartan, valsartan) and their fecal elim-
ination data. 
MATERIALS AND METHODS
The seven most often prescribed ARBs, candesartan, 
eprosartan, irbesartan, losartan, olmesartan, tel-
misartan and valsartan, were investigated (Table 1). 
The fecal elimination data of the investigated ARBs 
(Table 2) were obtained from the relevant literature 
(Lemke and Williams, 2008). The software package 
Molinspiration Depiction Software (Molinspira-
tion Cheminfirmatics) was used for the calculation 
of electronic descriptor - polar surface area (PSA); 
constitutional parameter - molecular weight (Mw); 
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and geometric descriptor - volume value (Vol). The 
ARBs lipophilicity descriptors, different logP values 
(AlogPs, AClogP, AB/logP, milogP, AlogP, MlogP, 
KOWWINlogP, XLOGP2, XLOGP3), as well as their 
aqueous solubility data (logS) were calculated using 
the software package Virtual Computational Chem-
istry Laboratory. Chemdraw ultra 12.0 was used for 
the calculation of another lipophilicity parameter, 
the ClogP values. 
Microsoft Excel 2003 and Origin 7.0 PRO (Or-
igin Lab Corporation, USA) were used to perform 
statistical analysis of the regression.
RESULTS 
According to the available literature data, the degree 
of ARBs fecal elimination varied from 42% to 97% 
(Table 2). The lowest values of fecal elimination were 
found in olmesartan medoxomil (around 42%), lo-
sartan (60%) and candesartan cilexetil (67%).
The five ARBs’ molecular descriptors (PSA, Mw, 
Vol, logP, logS) were calculated using different soft-
ware packages. The correlations between the ARBs 
elimination data obtained from relevant literature 
and the calculated descriptors were investigated by 
simple linear regression. Fecal elimination data and 
ARBs molecular descriptors (Vol, Mw and logS) 
showed low correlations with correlation coefficients 
(R2) around 0.2. The relationship between fecal elim-
ination and values of PSA provided correlation with 
R2 = 0.552., The relationship between different lipo-
philicity descriptors, logP values, and fecal elimina-
tion data were examined. The strongest correlation 
was found between ClogP and fecal elimination data 
(R2 = 0.725). 
In the next stage of the study, the relationship 
between fecal elimination data and two different 
ARB molecular descriptors were investigated with 
multiple linear regression (MLR). ClogP was chosen 
as the first independent variable since it showed the 
best correlations with ARB fecal elimination data. 
Solubility data (logS) was chosen as the second in-
dependent variable, since the correlations between 
ClogP values and all other calculated molecular de-
scriptors (Vol, Mw and PSA) provide R2 >0.3.
The values of predicted fecal elimination were 
calculated according to the following equation:
Fecal el.pred (%) = 14.431 (±2.294)ClogP + 
14.206(±4.993)logS + 69.673(±20.779)      Eq. 1.
where R2 = 0.909; S.D. = 7.030; F = 19.963.
The results obtained using MLR analysis apply-
ing two different descriptors as independent varia-
bles are presented in Table 3 and Fig. 1. 
The correlations found can be considered as 
good as those proposed by Asuero et al. (2006), with 
acceptable P, as well as F values, due to the limited 
Fig. 1. The relationship between ARBs fecal elimination data from literature (a) and predicted (b) fecal elimination data (using ClogP, 
and logS values) (R2 = 0.909). ARBs – Angiotensin II receptor antagonists; 1 – candesartan; 2 – eprosartan; 3 – irbesartan; 4 – losartan; 
5 – olmesartan; 6 – telmisartan; 7 – valsartan.
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number of compounds. The correlation that was 
found between the ARB fecal elimination data and 
the in silico molecular descriptors − lipophilicity pa-
rameter (ClogP) and aqueous solubility data (logS) − 
confirmed the high-throughput screening technique 
for the evaluation of fecal elimination of the selected 
compounds. 
DISCUSSION
The molecules with high lipophilicity show a higher 
degree of absorption, better penetration into tissues 
and distribution compared to less lipophilic ones 
with similar properties. Also, lipophilicity affects the 
duration of action of a drug, as well as the efficiency 
of its elimination. Namely, weakly lipophilic drugs 
are mostly eliminated by the urine, while highly li-
pophilic ones usually exhibit a high degree of fecal 
elimination. The drug present in the feces may rep-
resent the unabsorbed amount of an orally ingest-
ed dose, the amount of the dose that was absorbed 
but consequently excreted via the biliary route, or 
a combination of both. However, according to the 
available literature, it is still unclear whether ARB fe-
cal elimination includes unabsorbed drugs (Lemke 
and Williams, 2008; Sweetman, 2009). This is under-
standable since a drug’s absorption is highly affected 
by its lipophilicity, solubility, molecular size as well 
as other molecular properties. The Lipinski “rule of 
5” predicts low absorption or permeation for drugs 
with calculated logP greater than 5 and the molecu-
lar weight greater than 500 (Lipinski, 2000).
In this research seven ARBs (candesartan, epro-
sartan, irbesartan, losartan, olmesartan, telmisar-
tan and valsartan) were studied in order to evaluate 
the correlation between their fecal elimination data 
(ranging from 42-97%) obtained from relevant liter-
ature and calculated molecular descriptors. The main 
aim was to establish a high throughput approach us-
ing simple or multiple linear regression analysis ca-
pable of predicting the fecal elimination of selected 
Table 2. Fecal elimination data, calculated lipophilicity descriptor, ClogP values and aqueous solubility data (logS) of investigated ARBs.
Compound Fecal el. ClogP logS
Candesartan 67 5.44 -5.30
Eprosartan 90 5.05 -3.60
Irbesartan 80 6.05 -5.28
Losartan 60 4.10 -4.63
Olmesartan 42 2.76 -4.71
Telmisartan 97 7.46 -5.72
Valsartan 83 4.87 -4.86
ARBs – Angiotensin II receptor antagonists
Table 3. Fecal elimination of ARBs obtained from relevant literature (a) and predicted (b) from the MLR relation with calculated ClogP 
and logS values.
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ARBs. Several ARB molecular descriptors were cal-
culated using three different software packages. All 
calculated descriptors, electronic descriptor – PSA, 
constitutional parameter – Mw, geometric descriptor 
– Vol, lipophilicity descriptors - logP values (ClogP, 
AlogPs, AClogP, AB/logP, milogP, AlogP, MlogP, 
KOWWINlogP, XLOGP2, XLOGP3), as well as 
aqueous solubility data – logS, play important roles 
in drug absorption, distribution, metabolism and 
route of elimination. 
The correlations between the ARBs’ calculated 
molecular descriptors and the fecal elimination data 
obtained from the relevant literature were examined. 
The applicability of calculated molecular descriptors 
in ARBs elimination evaluation was established. Ac-
cording to the available literature, ARB pharmacoki-
netics, pharmacodynamics, efficacy and duration 
of action were investigated by a number of authors 
(Lacourcière and Asmar, 1999; Meredith et al., 2010; 
Meredith 2010). Different authors have suggested 
several assays that could be employed in investigat-
ing the elimination of different drugs (Hellstern et 
al., 1990; Kullak-Ublick and Becker, 2003; Verho et 
al., 1995; Martin et al., 2003). Nonetheless, most of 
these methods have certain limitations and a new 
fast, reliable and cost-effective evaluation of ARBs’ 
route of elimination should be developed. The rise in 
complexity and size of the average drug molecule, as 
well as its high logP values and low water solubility, 
can lead to a higher probability of drugs being rapid-
ly cleared metabolically or via biliary excretion (Li-
pinski, 2000; Ghose el al., 1999). Since a drug’s route 
and degree of elimination may affect its duration of 
action and activity, especially in patients with dam-
aged kidney function, the application of computed 
molecular descriptors in the prediction of drug elim-
ination are of great importance, especially for the 
newly synthesized drugs. 
The present study presents an effective technique 
that could be used for the fast and easy prediction of 
elimination route. The proposed methodology con-
firmed that lipophilicity, together with other molec-
ular properties, is essential in the route of elimination 
of drugs and could be regarded as a new, additional, 
in vitro approach appropriate for the modeling of 
elimination of the investigated group of ARBs. 
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